Evidence map›Paper›PMID 25583766›Full record

ArticleJournal of the National Comprehensive Cancer Network : JNCCN2015

Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia.

C Cameron Yin, Nitin Jain, Meenakshi Mehrotra, Jianhua Zhagn, Alexei Protopopov, Zhuang Zuo, Naveen Pemmaraju, Courtney DiNardo, Cheryl Hirsch-Ginsberg, Sa A Wang and 6 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Function of PML-RARA in Acute Promyelocytic Leukemia.Advances in experimental medicine and biology · 2024
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Pharmaceuticals (Basel, Switzerland) · 2021
    Article
  14. Review
  15. Review
  16. PLZF-RARCancers · 2020
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

C Cameron YinFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nitin JainFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Meenakshi MehrotraFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jianhua ZhagnFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Alexei ProtopopovFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zhuang ZuoFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Naveen PemmarajuFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Courtney DiNardoFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cheryl Hirsch-GinsbergFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sa A WangFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
L Jeffrey MedeirosFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lynda ChinFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Keyur P PatelFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Farhad RavandiFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Andrew FutrealFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Carlos E Bueso-RamosFrom the Departments of Hematopathology, Leukemia, Genomic Medicine, and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is characterized by the fusion of retinoic acid receptor alpha (RARA) with promyelocytic leukemia (PML) or, rarely, other gene partners. This report presents a patient with APL with a novel fusion between RARA and the interferon regulatory factor 2 binding protein 2 (IRF2BP2) genes. A bone marrow examination in a 19-year-old woman who presented with ecchymoses and epistaxis showed morphologic and immunophenotypic features consistent with APL. PML oncogenic domain antibody was positive. Results of fluorescence in situ hybridization, conventional cytogenetics, reverse transcription-polymerase chain reaction (RT-PCR), and oligonucleotide microarray for PML-RARA and common APL variant translocations were negative. Next-generation RNA-sequencing analysis followed by RT-PCR and direct sequencing revealed distinct breakpoints within IRF2BP2 exon 2 and RARA intron 2. The patient received all-trans retinoic acid, arsenic, and gemtuzumab ozogamicin, and achieved complete remission. However, the disease relapsed 10 months later, 2 months after consolidation therapy. This is the first report showing involvement of IRF2BP2 in APL, and it expands the list of novel RARA partners identified in APL.

Indexed as

Bone MarrowCarrier ProteinsChromosomes, Human, Pair 1Chromosomes, Human, Pair 17DNA-Binding ProteinsFemaleHigh-Throughput Nucleotide SequencingHumansLeukemia, Promyelocytic, AcuteNuclear ProteinsOncogene Proteins, FusionReceptors, Retinoic AcidRetinoic Acid Receptor alphaTranscription FactorsTranslocation, GeneticYoung AdultCarrier ProteinsDNA-Binding ProteinsIRF2BP2 protein, humanNuclear ProteinsOncogene Proteins, FusionRARA protein, humanReceptors, Retinoic AcidRetinoic Acid Receptor alphaTranscription Factors

Identifiers

PMID25583766
PMCPMC5843191

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.